Cargando…
Immunotherapeutic Targeting of GPC3 in Pediatric Solid Embryonal Tumors
Glypican 3 (GPC3) is a heparan sulfate proteoglycan and cell surface oncofetal protein which is highly expressed on a variety of pediatric solid embryonal tumors including the majority of hepatoblastomas, Wilms tumors, rhabdoid tumors, certain germ cell tumor subtypes, and a minority of rhabdomyosar...
Autores principales: | Ortiz, Michael V., Roberts, Stephen S., Glade Bender, Julia, Shukla, Neerav, Wexler, Leonard H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6401603/ https://www.ncbi.nlm.nih.gov/pubmed/30873384 http://dx.doi.org/10.3389/fonc.2019.00108 |
Ejemplares similares
-
Mesothelin: An Immunotherapeutic Target beyond Solid Tumors
por: Faust, Joshua R., et al.
Publicado: (2022) -
Targeted treatment of solid tumors in pediatric precision oncology
por: Bertacca, Ilaria, et al.
Publicado: (2023) -
Targeting GPC3(high) cancer-associated fibroblasts sensitizing the PD-1 blockage therapy in gastric cancer
por: Li, Dinuo, et al.
Publicado: (2023) -
Nanomedicines targeting activation of STING to reshape tumor immune microenvironment and enhance immunotherapeutic efficacy
por: Chen, Shanshan, et al.
Publicado: (2023) -
Glioma Stem Cells as Immunotherapeutic Targets: Advancements and Challenges
por: Piper, Keenan, et al.
Publicado: (2021)